AlphAIAlphAI — Financial news for AI agents
tipranks.comOCT 212 min read$IART

Integra LifeSciences reports Q3 adjusted EPS 59c, consensus 56c

Integra LifeSciences reported Q3 adjusted EPS of 59c, beating consensus of 56c, while revenue was $411.2M, slightly missing the $412.1M estimate. CEO Stuart Essig noted mixed results across their portfolio, with strong cash flow and completed debt refinancing. Analysts have recently lowered price targets for the company.

Original reporting
tipranks.com
Published Oct 21, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IART
Neutral
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$IARTNeutralMed
01

Why it matters

Earnings beat may provide short‑term support, but operational disruptions and revenue miss could limit upside.

02

Market read

First‑report earnings release for a mid‑cap med‑tech company; modest impact on sector.

03

What to watch

Potential impact of the $7M Cincinnati disruption on future margins.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Integra LifeSciences operates in specialty surgery and tissue reconstruction, recently completed a debt refinancing.

Company-level read

Ticker impact

$IARTNeutralHigh confidence
Context

Integra LifeSciences reported Q3 adjusted EPS of $0.59 versus consensus $0.56 and revenue of $411.2M versus $412.1M consensus.

Expected impact

likely modest upward pressure as the market prices in the EPS beat

Evidence & confidence

The earnings surprise is small and the revenue shortfall is minimal, suggesting limited but positive price movement.

Market effects

Sector

Healthcare devices sector sees a mixed earnings season with a few modest beats.

Regional

U.S. markets may see slight positive bias in related med‑tech stocks.

Global

Limited; primarily affects U.S. listed med‑tech equities.

Counterpoint

What could challenge this read

The revenue miss could signal underlying demand weakness, outweighing the EPS beat.

Key entities

  • Executive
    Stuart Essig

    Chairman and CEO of Integra LifeSciences, provided commentary on Q3 results.

Read at source← All news

StoryIntegra LifeSciences reports Q3 2026 results, cites $7 M flood hit, completes $2.1 B refinancing and trims Q4 outlook

Also covered by

5 outlets

Related articles

OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min
OCT 21
$IARTHighAI 8/10

Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

finance.yahoo.com3 min
OCT 21
$IARTHigh

Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

tradingview.com2 min
OCT 21
Med

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.

finance.yahoo.com2 min
OCT 21
$IARTMed

Why Integra LifeSciences (IART) stock is falling today

Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.

financialcontent.com2 min